MAIA Biotechnology terminates ATM equity offering agreement after raising ~$5.68M

MAIA Biotechnology, Inc.

Suspended sales and gave notice to terminate At The Market Offering Agreement with H.C. Wainwright, effective 7 business days after May 14, 2026.
Since March 28, 2025 prospectus supplement for $11.2M, sold 3,116,012 shares for gross proceeds of approx. $5,680,924.
No further sales under the ATM facility; termination will be effective upon expiration of the notice period.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MAIA Biotechnology, Inc. terminated At The Market Offering Agreement with H.C. Wainwright & Co., LLC (effective 2026-05-14).

Action: termination
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Effective: 2026-05-14

Exact text from the filing

On May 14, 2026, MAIA Biotechnology, Inc. (the “Company”) suspended sales of its common stock, par value $0.0001 per share (“Common Stock”), pursuant to that certain At The Market Offering Agreement dated February 14, 2024, or the sales agreement, between the Company and H.C. Wainwright & Co., LLC (the “Agent”), the Company’s sales agent thereunder, and provided notice to the Agent that it is terminating the sales agreement, which termination will be effective 7-business days after May 14, 2026, in accordance with the terms of the sales agreement.

View on SEC.gov

Browse all material agreements →

MAIA Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-023168

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.